Table 1 Main clinical characteristics of the two IPF GSVA clusters in D#1. Statistically significant results are highlighted in bold
From: Lung immune signatures define two groups of end-stage IPF patients
Cluster 1 | Cluster 2 | p-value | |||||
|---|---|---|---|---|---|---|---|
n | mean | SD | n | mean | SD | ||
Age | 54 | 63.67 | 8.73 | 46 | 66.91 | 7.24 | 0.048 |
Weight (kg) | 55 | 88.36 | 17.31 | 47 | 91.73 | 18.05 | 0.338 |
BMI | 55 | 30.48 | 4.97 | 47 | 30.67 | 5.82 | 0.852 |
Smoking (pack/year) | 39 | 28.45 | 24.3 | 27 | 23.02 | 18.25 | 0.329 |
Quit smoking (years) | 39 | 21.11 | 13.47 | 27 | 24.25 | 13.92 | 0.361 |
GAP score (1–7) | 60 | 4.64 | 1.23 | 49 | 4.94 | 1.16 | 0.207 |
Lung function test | |||||||
Predicted DLCO | 55 | 29.37 | 5.69 | 47 | 30.35 | 4.9 | 0.357 |
Predicted FEV1 | 55 | 69.56 | 16.54 | 47 | 73.77 | 18.74 | 0.232 |
Predicted FVC | 55 | 63.15 | 14.87 | 47 | 66.57 | 18.43 | 0.301 |
FEV1/FVC | 55 | 0.83 | 0.06 | 47 | 0.83 | 0.06 | 0.973 |
TAC | |||||||
Total Segmented Volume with density less than -950 HU (cm2) | 29 | 155.27 | 140.98 | 21 | 244.15 | 164.3 | 0.044 |
Lower Attenuation areas (cm2) | 29 | 4.38 | 3.42 | 21 | 6.08 | 3.22 | 0.080 |
Ground Glass Opacity (cm2) | 29 | 17.15 | 14.38 | 21 | 11.22 | 11.11 | 0.119 |
Honeycombing (cm2) | 29 | 1.2 | 1.95 | 21 | 1.27 | 1.24 | 0.893 |
Normal (cm2) | 29 | 52.86 | 13.69 | 21 | 46.99 | 16.22 | 0.169 |
Reticular densities (cm2) | 29 | 4.14 | 3.03 | 21 | 4.47 | 3.56 | 0.719 |
Vessels (cm2) | 29 | 5.62 | 2 | 21 | 5.14 | 1.88 | 0.398 |
Categorical variables | |||||||
Short of breath when talk, n (%) | 60 | 34 (56.7) | 49 | 16 (32.6) | 0.023 | ||
Cough disturbs sleep, n (%) | 60 | 37 (45) | 49 | 10 (20.4) | 0.014 | ||
Long time to wash or dress, n (%) | 60 | 22 (36.7) | 49 | 6 (2.2) | 0.007 | ||
Chronic bronchitis, n (%) | 60 | 7 (12.1) | 49 | 0 (0.0) | 0.044 | ||